EDEliso M. Dzhobava

Eliso M. Dzhobava

*This is an algorithmically generated author record based on publicly available information.

Eliso M. Dzhobava has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Experience in the use of peptide bioregulators and nutrient priming in a patient in early perimenopause

    by I.G. Knysheva, E.M. Dzhobava

    The article presents a clinical observation of a patient with early perimenopause, which developed against the background of somatic pathology and chronic stress. Based on the analysis of complaints, medical history, and clinical and laboratory examination data in the dynamics according to the stages of reproductive aging (–2 and –1) on the STRAW+10 scale, an individual treatment regimen was selected taking into account the patient’s wishes, nutritional priming* (focused nutritional support aimed at improving the regulation of the hormonal system) and therapy were performed. peptide bioregulators (biologically active substances based on peptides) with a positive result.

  • Open Access

    Depression in postmenopause: interdisciplinary approach in management and perspectives for rehabilitation

    by D. V. Blinov, E. S. Akarachkova, D. M. Ampilogova, E. M. Dzhobava, V. I. Tsibizova, A. G. Solopova, N. V. Pavlova, D. I. Korabelnikov, D. A. Petrenko

    Surgical and natural menopause is often associated with depression symptoms. Along with the postpartum period, perimenopause is a “window of vulnerability” for depression development, because decline in estrogen level accounts for extinction of reproductive function, emotional disorders, genitourinary menopausal syndrome, which are combined with non-endocrine risk factors, such as decreasing income levels, low social support, and stress. Although a direct relationship between blood estrogens level and depression has not been demonstrated, the relation between menopause symptoms and depression has been proven, i.e., the symptoms of menopause can be considered as risk factors. Here, we summarizes the current view on the correct counseling and routing of menopausal women with depression symptoms in primary health care facilities, the principles of managing patients with risk factors, including genitourinary menopausal syndrome, as well as methods of rehabilitation and informational support. This will aid to improve the quality of medical care for such patients.


  • Open Access

    Hereditary angioedema. Clinical guidelines. (D84.1)

    by Elena A. Bliznetz, Ekaterina A. Viktorova, Elena A. Vishneva, Eliso M. Dzhobava, Natalya I. Il'INa, Natalia B. Kuzmenko, Elena A. Latysheva, Tatiana V. Latysheva, Irina A. Manto, Leyla S. Namazova-Baranova, et al.

    Hereditary angioedema is a rare, potentially life-threatening genetic disease that manifests with skin and mucous/submucosal swelling that occurs under the influence of bradykinin. The clinical guidelines for hereditary angioedema (code for the International Statistical Classification of Diseases and Related Health Problems D84.1) were developed in December 2020 by the Russian Association of Allergology and Clinical Immunology, Association of Medical Geneticists, National Association of Experts in the Field of Primary Immunodeficiencies, Union of Pediatricians of Russia. In December 2020, the project was approved at a meeting of the Scientific and Practical Council of the Ministry of Health of the Russian Federation (December 10, 2020 No. 743/12). The clinical guidelines are devoted to optimizing the clinical care of patients with hereditary angioedema. The topic is relevant owing to the under-diagnosis of hereditary angioedema and insufficient awareness of doctors of various specialties about this problem, as well as the difficulties in managing this category of patients. The clinical guidelines contain information about the epidemiology, etiology, classification, pathogenesis, and common clinical manifestations of hereditary angioedema. Thus, the paper described actual diagnostic approaches and differential diagnosis of hereditary angioedema and established its diagnostic criteria. Medical care algorithms to patients with hereditary angioedema at the prehospital and hospital stages are also described. The principles of pharmacotherapy, including long-term prophylaxis, short-term prophylaxis, and acute therapy, for hereditary angioedema are also presented. Treatment regimens are stratified according to patients age and gender. Non-drug measures for the prevention hereditary angioedema attacks are considered. Sections were also added in the edition of the new clinical guidelines of hereditary angioedema. Clinical guidelines for hereditary angioedema are intended for practicing doctors of all specialties, students and teachers of medical universities, residents, graduate students of medical universities.